Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2020 / 09:15PM GMT
Release Date Price: €24 (+2.56%)
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst

Good morning. So my name is Dave Risinger. I cover U.S. pharmaceuticals at Morgan Stanley, and it's very much my pleasure to introduce leadership from Revance.

I do need to read a disclaimer just very quickly. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. It's not for members of the press. And if you're a member of the press, please disconnect and reach out separately. For important disclosures, please see www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.

So it's very much my pleasure to welcome both Mark Foley, who's the President and CEO of Revance; and Toby Schilke, who's the CFO of the company, for a discussion this afternoon.

I thought it would be best to have each of them introduce themselves briefly. Obviously, they

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot